Are Your GSA Schedule Products TAA-Compliant?
Client Alert | less than 1 min read | 10.08.14
While Multiple Award Schedules administered by GSA can be a valuable tool for selling to government customers, these government-wide contracts include numerous special requirements, including the requirement that each and every product offered comply with the Trade Agreements Act restriction on providing products from so-called "non-designated countries." In "Where Are Your Products From? The Importance and Challenges of Managing TAA Compliance for GSA Schedule Holders", published in Bloomberg BNA Federal Contracts Report, C&M's Cathy Kunz and Addie Cliffe discuss recent enforcement actions that highlight the risk of TAA non-compliance and offer practical pointers for assuring compliance.
Contacts
Insights
Client Alert | 9 min read | 10.21.26
The life sciences sector is uniquely vulnerable to the inherent risks of AI-generated evidence in drug development and discovery. This client alert focuses on five core challenges: hallucinations, skewed predictions from unrepresentative training data, the opacity of AI reasoning, input sensitivity that undermines reproducibility, and adversarial manipulation of training data. To address these risks, companies should use experimental validation and human oversight as the common legal and regulatory safety net. This entails among other measures auditing AI outputs, characterizing training data, and structural oversight. Companies also should prepare for evolving frameworks and guidance from the U.S. Food and Drug Administration (FDA) and the European Union (EU) that address use of AI in drug discovery and development .
Client Alert | 2 min read | 10.21.26
Client Alert | 3 min read | 10.21.26
Private Investigations Act Series: Temporal, material and territorial scope
Client Alert | 7 min read | 10.21.26
